The estimated Net Worth of Thomas G Lynch is at least $1.52 Milion dollars as of 31 March 2020. Mr. Lynch owns over 37,500 units of Evofem Biosciences Inc stock worth over $2,925 and over the last 7 years he sold EVFM stock worth over $0. In addition, he makes $1,515,000 as Chairman of the Board at Evofem Biosciences Inc.
Sign up
Mr. Lynch EVFM stock SEC Form 4 insiders trading
Thomas has made over 6 trades of the Evofem Biosciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 37,500 units of EVFM stock worth $338 on 31 March 2020.
The largest trade he's ever made was buying 100,000 units of Evofem Biosciences Inc stock on 14 August 2018 worth over $226,000. On average, Thomas trades about 27,083 units every 53 days since 2018. As of 31 March 2020 he still owns at least 325,000 units of Evofem Biosciences Inc stock.
You can see the complete history of Mr. Lynch stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Thomas Lynch biography
Thomas Lynch serves as Chairman of the Board of the Company. Mr. Lynch also currently serves as Chairman of the Boards of Profectus Biosciences Inc. and Adherium Limited, positions he has held since 2006 and 2016, respectively, and since 2010 as a non-executive director of GW Pharmaceuticals where he serves as Chairman of both its remuneration compensation committee and as a member of its audit committees. Mr. Lynch has served as the non-executive chairman of the Ireland East Hospital Group and the Mater Misericordiae University Hospital, a non-profit charitable foundation providing acute hospital services to both public patients funded by the HSE (defined below) and private patients since 2017 and 2006, respectively. Mr. Lynch serves on the board of a number of privately held biotechnology companies. Mr. Lynch previously served as Chairman of ICON PLC and was a member of its board for 21 years. Mr. Lynch was the Chairman and Chief Executive Officer of Amarin Corporation PLC from 2000 to 2010, Executive Vice President, Chief Financial Officer and director of Elan Corporation PLC from 1993 to 2004, and the founder and director of Warner Chilcott PLC from 1994 to 2002. From 2001 to 2010, Mr. Lynch was a member of the Board of IDA Ireland (an Irish government investment agency). Mr. Lynch received his B.Sc. in Economics from Queen’s University of Belfast in 1978, and qualified as a chartered accountant with KPMG in 1983 and served as a partner in that firm from 1990 to 1993.
What is the salary of Thomas Lynch?
As the Chairman of the Board of Evofem Biosciences Inc, the total compensation of Thomas Lynch at Evofem Biosciences Inc is $1,515,000. There are 3 executives at Evofem Biosciences Inc getting paid more, with Saundra Pelletier having the highest compensation of $2,803,980.
How old is Thomas Lynch?
Thomas Lynch is 63, he's been the Chairman of the Board of Evofem Biosciences Inc since 2018. There are 2 older and 12 younger executives at Evofem Biosciences Inc. The oldest executive at Evofem Biosciences Inc is Gillian Greer, 75, who is the Independent Director.
What's Thomas Lynch's mailing address?
Thomas's mailing address filed with the SEC is C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO, CA, 92130.
Insiders trading at Evofem Biosciences Inc
Over the last 7 years, insiders at Evofem Biosciences Inc have traded over $32,368,585 worth of Evofem Biosciences Inc stock and bought 12,978,479 units worth $54,857,186 . The most active insiders traders include Research Corp Acacia, Fund Solutions Ltd Link a Biopharma, Inc. Pdl. On average, Evofem Biosciences Inc executives and independent directors trade stock every 38 days with the average trade being worth of $5,281. The most recent stock trade was executed by Yan Zhang on 12 January 2024, trading 104 units of EVFM stock currently worth $4.
What does Evofem Biosciences Inc do?
evofem is a biotechnology company focusing on developing innovative reproductive health products for women in every global market. evofem develops and markets products that are woman-controlled, non-invasive and rapidly reversible. women need access to effective products that are well suited to their lifestyle and consistent with their core values. products include: amphora™ - a non-hormonal vaginal gel being investigated for contraceptive and microbicidal properties.
What does Evofem Biosciences Inc's logo look like?
Complete history of Mr. Lynch stock trades at GW Pharmaceuticals a Evofem Biosciences Inc
Evofem Biosciences Inc executives and stock owners
Evofem Biosciences Inc executives and other stock owners filed with the SEC include:
-
Saundra Pelletier,
President, Chief Executive Officer, Director -
Kelly Culwell,
Chief Medical Officer -
Saundra Pelletier,
Pres, CEO & Director -
Thomas Lynch,
Chairman of the Board -
Russell Barrans,
Chief Commercial Officer -
Justin File,
Chief Financial Officer -
Justin J. File,
Chief Financial Officer -
Russell Barrans,
Chief Commercial Officer -
Tony O'Brien,
Independent Director -
William Hall,
Independent Director -
Colin Rutherford,
Independent Director -
Gillian Greer,
Independent Director -
Kim Kamdar,
Independent Director -
Amy Raskopf,
IR Contact Officer -
Lisa Rarick,
Independent Director -
Alexander Fitzpatrick,
Executive Vice President, General Counsel, Secretary -
Dr. Kelly Culwell M.D.,
Chief Medical Officer -
Kathy Gallo-Doyle,
VP of Sales -
Alexander A. Fitzpatrick Esq.,
Exec. VP, Gen. Counsel & Sec. -
Biopharma, Inc. Pdl,
10% owner -
Research Corp Acacia,
10% owner -
Anthony Stephen O'brien,
Director -
Yan Zhang,
CFO -
Ltd. Invesco,
10% owner -
Fund Solutions Ltd Link,
10% owner